Kaedi Bio develops a synthetic biology CAR-T discovery platform that integrates CAR-T cell therapy research with personalized medical services for targeted cancer treatment. This approach enables the creation of individualized therapies that enhance tumor immune response, addressing the need for more effective cancer care solutions.
Funding
Funding not disclosed
Founders
Product
Problem
Current CAR-T cell therapies face challenges in effectively targeting solid tumors and overcoming issues such as limited persistence, off-target effects, and the immunosuppressive tumor microenvironment. Traditional methods of antibody development and immune cell engineering are often time-consuming and costly.
Solution
Kaedi Bio develops a synthetic biology CAR-T discovery platform, KD-SmCAR TM, to create novel, targeted cancer treatments. The platform integrates CAR-T cell therapy research with personalized medical services, enabling the design and development of individualized therapies. By leveraging synthetic biology, Kaedi Bio engineers CAR-T cells with enhanced tumor immune response and improved specificity. The KD-SmCAR TM platform supports the development of next-generation CAR-T therapies, including dual-targeting, triple-targeting, and allogeneic universal CAR-T cells, addressing the limitations of existing approaches in treating hematological malignancies and solid tumors.
Target Audience
The primary target audience includes cancer researchers, clinical oncologists, and biopharmaceutical companies focused on developing advanced CAR-T cell therapies and personalized cancer treatments.
Features
- KD-SmCAR TM synthetic biology platform for rapid CAR-T development
- Development of next-generation CAR-T therapies: dual-targeting, 4th-generation CAR-T; triple-targeting, 5th-generation CAR-T; and allogeneic universal CAR-T
- Gene editing capabilities using CRISPR/Cas9 system for targets such as PD1, TCR-α, and CD52
- Expertise in developing immuno-oncology antibodies for targeted cancer therapy
- Focus on overcoming challenges in solid tumor treatment
- Development of nucleic acid drugs for targeting previously undruggable proteins